Special Considerations in the Use of Direct Oral Anticoagulants (DOACs)

Expires February 20, 2021


Video length: 53 minutes

This month’s “Virtual Lecture” focuses on special considerations in the use of DOACs. Ariela Marshall, M.D., will discuss treatment of cancer-associated venous thromboembolism (VTE) and the outcomes of DOACs as well as DOAC and antiphospholipid syndrome (APS) and heparin-induced thrombocytopenia (HIT). Then, Waldemar Wysokinski, M.D., Ph.D., will discuss the reversal of DOACs and outcomes.



Upon completion of this activity, participants should be able to:

  • Discuss the results of two major DOAC clinical trials in cancer-associated VTE.
  • Review the pathophysiology and current treatment options for patients with APS and HIT.
  • Summarize the current state of the evidence regarding use of DOACs in clinical situations.
  • Determine when and how to reverse anticoagulation.


Intended Audience

This program is designed for practicing clinicians, primary care providers, hematologists, cardiologists, neurologists, hospitalists, vascular medicine specialists, nurse practitioners, pharmacists, physician assistants, nurses, and laboratory scientists and technologists whose practices and interests include aspects of thrombotic disorders.



Photo of Ariela Marshall, M.D.Ariela Marshall, M.D.
Assistant Professor of Laboratory Medicine and Pathology
Department of Hematology
Mayo Clinic, Rochester, Minnesota




Photo of Waldemar Wysokinski, M.D., Ph.D.Waldemar Wysokinski, M.D., Ph.D.
Professor of Medicine
Department of Cardiovascular Diseases
Mayo Clinic, Rochester, Minnesota




Level of instruction




The following types of credit are offered for this program:

State of California
State of Florida

To obtain credit:

  1. Watch the video.
  2. Complete the posttest and evaluation that launches immediately following the video.
  3. Generate and print your certificate(s).



Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1 P.A.C.E® contact hour.

State of California

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for Clinical Laboratory Sciences for State of California. This program has been approved for 1 contact hour.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General (Hematology) credit. This program has been approved for 1 contact hour.

MCL Education (@mmledu)

MCL Education

This post was developed by our Education and Technical Publications Team.